Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally

NCT00083538 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Dexamethasone
DRUG: Thalidomide
DRUG: Cisplatinum
DRUG: Adriamycin
DRUG: Cyclophosphamide
DRUG: Etoposide

Sponsor

University of Arkansas